Abstract library

321 results for "Sass".
#936 Promoter Hypermethylation at RASSF1 is a Feature of Small Intestinal Neuroendocrine Tumors
Introduction: Promoter hypermethylation of RASSF1 has been reported in many tumor types.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Anna Karpathakis
Authors:
#487 Validation of Chromogranin A Assays in Patients with Neuroendocrine Tumors
Introduction: CgA is the most important biochemical marker for evaluation of NETs. Different assays with different accuracy exist.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Lise Brehm Høj
Authors:
Keywords: neuroendocrine, CgA, assay
#783 A Comparison of Three Chromogranin A Assays in Patients with Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is the most important general tumor marker used in the diagnosis and follow-up of patients with neuroendocrine tumors (NET). CgA assays may have different sensitivities, which is of importance for the clinical diagnosis and handling of NET patients.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Dr. Henning Grønbæk
Authors:
#844 Variation Between Chromogranin A Assays in the Diagnosis of Gastric Carcinoid Type 1
Introduction: Chromogranin A (CgA) is not very accurate for the diagnosis of gastric carcinoid type1 (GC1). Clinical interpretation of CgA results may be affected by the heterogeneity between CgA assays. The commercial CgA assay, DAKO (DAKO, Denmark A/S, Glostrup, Denmark) is an ELISA which recognizes a 23 kD C terminal fragment of CgA; the Imperial Supra-regional Assay Service radioimmunoassay (SAS Hammersmith Hospital, Imperial College, London) is a competitive radioimmunoassay raised against the whole pancreastatin molecule.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: MD Roberta E Rossi
Authors:
#59 Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors
Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Georgios Kanakis
Authors:
#163 Clinical value of MRI DWI and (Gd-EOB)-DTPA to assess liver involvement in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Introduction: Standard MRI, including breath-hold techniques with SE T1 and T2 weighted images, biochemical shift, and 3D GRE and also T1 images after gadolinium enhancement Gd-DTPA, are useful in detecting liver lesions in patients with advanced GEP-NET. Recently, new algorithms of MRI, including diffusion-weighted imaging MRI (DWI) and i.v. (Gd-EOB)-DTPA (Primovist) contrast enhancement, seems to be promising in the detection of liver deposits.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jaroslaw B Cwikla
Authors:
#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Anders Öhberg
Authors:
#1606 Tumor Growth Rate to Assess Tumor Activity in Patients with Lung Neuroendocrine Tumors on Lanreotide Autogel: A Case-Series Analysis
Introduction: The slow-growing character of neuroendocrine tumors (NET) makes it difficult to assess treatment impact on tumor growth.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Frank van Fraeyenhove
Authors:
#1714 CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN)
Introduction: The presence of CTCs confers adverse prognosis in metastatic NET pts with heterogenous treatment history. Post treatment CTC count correlates with disease progression and overall survival.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Kate Higgs
Authors:
#1851 Ecological Study to Assess the Management of Gastroenteropancreatic Neuroendocrine Tumors in Spain
Introduction: Neuroendocrine tumors (NET) have widely varying characteristics, localizations, and treatments. Consequently, a multidisciplinary approach to diagnosis and treatment is necessary. Given the heterogeneous management of this disease, we conducted an ecological survey to assess usual clinical practice in Spain.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Raquel Guardeño
Authors: